Portola, BMS, Pfizer Team Up to Test Their Drugs' Antidote
By Randy Osborne
Staff Writer
Staff Writer
Friday, November 2, 2012
Not every day do you see a company, in the course of developing its drug, sign a deal with two other firms that are working on a therapy in the same class. Even more unusual: The deal is designed to help come up with a reversing agent for both compounds, and others.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.